Press Releases
April 6, 2020
SBP Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer
March 24, 2020
SBP Provides Business Update and Reports Operating Results for FY2019
- Enrollment completed in fourth cohort of Phase 1a/1b trial of SBP-101 in pancreatic cancer; expansion cohort initiated
- Interim Phase 1 data presented at ASCO GI meeting demonstrated tolerability and tumor response in treatment-naïve patients with metastatic pancreatic cancer
January 28, 2020
SBP Initiates Search for CEO
Company founder Dr. Michael T. Cullen intends to continue to serve as Executive Chairman and will continue to serve as President and CEO until a successor is named
January 24, 2020
SBP Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium
- SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel
- Objective Response Rate (ORR) was 62% by RECIST criteria
- Study expansion in patients with pancreatic cancer planned to begin in Q2
View/download press release »
View/download poster presentation »
December 22, 2019
SBP Announces Data Presentation at the ASCO 2020 Annual Gastrointestinal Cancers Symposium
Biotech Executive Arthur Fratamico Recently Joined Board of Directors
View/download press release »
View/download poster presentation »
November 15, 2019
SBP Provides a Business Update and Reports Q3 2019 Financial Results
- Enrollment in Third Cohort of the PDA Combination Study completed; Fourth Cohort planned
- New U.S. sites added in anticipation of further clinical development
- Company raised $3.1 million in new capital
August 13, 2019
SBP Provides a Business Update and Files Report for Q2 2019
- Enrollment in Third Cohort of PDA Combination Study is Encouraging
- Preliminary Efficacy Signals Improve with New Data Regarding Second Cohort
- Entire $2.3 million Owed under Convertible Notes Converted to Equity
July 22, 2019
SBP Provides an Update on Ongoing Front-line Pancreatic Cancer Clinical Trial
- Preliminary Efficacy Signals Seen with SBP-101 Administered in Combination with Gemcitabine and Nab-paclitaxel
- DSMB Approves Enrollment of 3rd and Final Cohort
May 14, 2019
SBP Provides a Business Update and Files Report for Q1 2019
- Enrollment in Second Cohort of PDA Combination Study Completed
- New Funding Totaling $0.8 Million Secured
March 22, 2019
SBP Provides Business Update and Files Annual Report for 2018
Events & Presentations